TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
Hasako, Shinichi, Terasaka, Miki, Abe, Naomi, Uno, Takao, Ohsawa, Hirokazu, Hashimoto, Akihiro, Fujita, Ryoto, Tanaka, Kenji, Okayama, Takashige, Wadhwa, Renu, Miyadera, Kazutaka, Aoyagi, Yoshimi, Yonekura, Kazuhiko, Matsuo, Kenichi
Published in Molecular cancer therapeutics (01.08.2018)
Published in Molecular cancer therapeutics (01.08.2018)
Get full text
Journal Article
MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel
Shimomura, Toshiyasu, Hasako, Shinichi, Nakatsuru, Yoko, Mita, Takashi, Ichikawa, Koji, Kodera, Tsutomu, Sakai, Takumi, Nambu, Tadahiro, Miyamoto, Mayu, Takahashi, Ikuko, Miki, Satomi, Kawanishi, Nobuhiko, Ohkubo, Mitsuru, Kotani, Hidehito, Iwasawa, Yoshikazu
Published in Molecular cancer therapeutics (01.01.2010)
Published in Molecular cancer therapeutics (01.01.2010)
Get full text
Journal Article
Muscle RAS oncogene homolog (MRAS) recurrent mutation in Borrmann type IV gastric cancer
Yasumoto, Makiko, Sakamoto, Etsuko, Ogasawara, Sachiko, Isobe, Taro, Kizaki, Junya, Sumi, Akiko, Kusano, Hironori, Akiba, Jun, Torimura, Takuji, Akagi, Yoshito, Itadani, Hiraku, Kobayashi, Tsutomu, Hasako, Shinichi, Kumazaki, Masafumi, Mizuarai, Shinji, Oie, Shinji, Yano, Hirohisa
Published in Cancer medicine (Malden, MA) (01.01.2017)
Published in Cancer medicine (Malden, MA) (01.01.2017)
Get full text
Journal Article
Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo
Hirai, Hiroshi, Shimomura, Toshiyasu, Kobayashi, Makiko, Eguchi, Tomohiro, Taniguchi, Eri, Fukasawa, Kazuhiro, Machida, Takumitsu, Oki, Hiroko, Arai, Tsuyoshi, Ichikawa, Koji, Hasako, Shinichi, Haze, Kyosuke, Kodera, Tsutomu, Kawanishi, Nobuhiko, Takahashi-Suziki, Ikuko, Nakatsuru, Yoko, Kotani, Hidehito, Iwasawa, Yoshikazu
Published in Cell cycle (Georgetown, Tex.) (15.04.2010)
Published in Cell cycle (Georgetown, Tex.) (15.04.2010)
Get full text
Journal Article
TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
Udagawa, Hibiki, Hasako, Shinichi, Ohashi, Akihiro, Fujioka, Rumi, Hakozaki, Yumi, Shibuya, Mikiko, Abe, Naomi, Komori, Toshiharu, Haruma, Tomonori, Terasaka, Miki, Fujita, Ryoto, Hashimoto, Akihiro, Funabashi, Kaoru, Yasuda, Hiroyuki, Miyadera, Kazutaka, Goto, Koichi, Costa, Daniel B, Kobayashi, Susumu S
Published in Molecular cancer research (01.11.2019)
Published in Molecular cancer research (01.11.2019)
Get full text
Journal Article
Abstract A158: Characterization of antitumor activity of TAS6417, a novel EGFR-TKI targeting exon 20 insertions
Hasako, Shinichi, Terasaka, Miki, Fujita, Ryoto, Abe, Naomi, Hashimoto, Akihiro, Matsuo, Kenichi, Utsugi, Teruhiro, Iwasawa, Yoshikazau
Published in Molecular cancer therapeutics (01.01.2018)
Published in Molecular cancer therapeutics (01.01.2018)
Get full text
Journal Article
Abstract 1329: Preclinical evaluation of TAS6417 as a highly effective, pan-mutation-selective EGFR tyrosine kinase inhibitor
Udagawa, Hibiki, Hasako, Shinichi, Ohashi, Akihiro, Abe, Naomi, Haruma, Tomonori, Komori, Toshiharu, Terasaka, Miki, Fujita, Ryoto, Funabashi, Kaoru, Yasuda, Hiroyuki, Miyadera, Kazutaka, Goto, Koichi, Costa, Daniel B., Kobayashi, Susumu S.
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Get full text
Journal Article